Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Recruiting · NCT06482801 · Registry updated 2024-07-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver cancer, liver disorder, neoplasm | Recruiting | Phase 2 | 2024-07-01 | NCT06482801 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Second Affiliated Hospital of Guangzhou Medical University | 70 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | China | 4 |